Intra-Cellular Therapies Inc. (ITCI), a commercial-stage biopharmaceutical company developing therapies for neuropsychiatric conditions, anticipates achieving several milestones this year.
The company's sole marketed drug is Caplyta (lumateperone), an atypical antipsychotic for the treatment of schizophrenia and bipolar depression. The drug, which is in capsule formylation, received FDA approval for the treatment of schizophrenia in adults in Dec.2019, and for bipolar depression in adults in Dec.2021.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com